Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operating activities of $743 million in ...

Merck (MRK) is a leading global healthcare company recognized for its groundbreaking pharmaceutical products and vaccines.

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...

The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...